ArticlePloS one2009
The internally truncated LRP5 receptor presents a therapeutic target in breast cancer.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 64 citations in OpenAlex.
- Review
- Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2025Review
- Recurrent UBE3C-LRP5 translocations in head and neck cancer with therapeutic implications.NPJ precision oncology · 2024Article
- Invention of 3Mint for feature grouping and scoring in multi-omics.Frontiers in genetics · 2023Article
- Biophysical Survey of Small-Molecule β-Catenin Inhibitors: A Cautionary Tale.Journal of medicinal chemistry · 2022Review
- Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.Cancer research · 2022Article
- Wnt Signaling in the Breast: From Development to Disease.Frontiers in cell and developmental biology · 2022Review
- LRP5 Regulates HIF-1α Stability via Interaction with PHD2 in Ischemic Myocardium.International journal of molecular sciences · 2021Article
- P-cadherin mutations are associated with high basal Wnt activity and stemness in canine mammary tumor cell lines.Oncotarget · 2019Article
- Gap Junctions and Wnt Signaling in the Mammary Gland: a Cross-Talk?Journal of mammary gland biology and neoplasia · 2019Review
- Dishevelled: A masterful conductor of complex Wnt signals.Cellular signalling · 2018Review
- LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers.Oncotarget · 2018Article
- Characterization of mammary-specific disruptions for Tph1 and Lrp5 during murine lactation.Scientific reports · 2017Article
- The crossroads of breast cancer progression: insights into the modulation of major signaling pathways.OncoTargets and therapy · 2017Review
- Review
- Cooperative antiproliferative signaling by aspirin and indole-3-carbinol targets microphthalmia-associated transcription factor gene expression and promoter activity in human melanoma cells.Cell biology and toxicology · 2016Article
- Alternative splicing within the Wnt signaling pathway: role in cancer development.Cellular oncology (Dordrecht, Netherlands) · 2016Review
- Downregulation of human Wnt3 in gastric cancer suppresses cell proliferation and induces apoptosis.OncoTargets and therapy · 2016Article
- Lrp5 Has a Wnt-Independent Role in Glucose Uptake and Growth for Mammary Epithelial Cells.Molecular and cellular biology · 2015Article
- Targeting the WNT Signaling Pathway in Cancer Therapeutics.The oncologist · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is a common malignant disease, which may be caused by a number of genes deregulated by genomic or epigenomic events. Deregulated WNT/beta-catenin signaling with accumulation of beta-catenin is common in breast tumors, but mutations in WNT signaling pathway components have been rare. An aberrantly spliced internally truncated LRP5 receptor (LRP5Delta666-809, LRP5Delta) was shown recently to be resistant to DKK1 inhibition, and was required for beta-catenin accumulation in hyperparathyroid tumors and parathyroid tumor growth. METHODOLOGY/PRINCIPAL
findingsHere we show, by reverse transcription PCR and Western blot analysis, that LRP5Delta is frequently expressed in breast tumors of different cancer stage (58-100%), including carcinoma in situ and metastatic carcinoma. LRP5Delta was required in MCF7 breast cancer cells for the non-phosphorylated active beta-catenin level, transcription activity of beta-catenin, cell growth in vitro, and breast tumor growth in a xenograft SCID mouse model. WNT3 ligand, but not WNT1 and WNT3A augmented the endogenous beta-catenin activity of MCF7 cells in a DKK1-insensitive manner. Furthermore, an anti-LRP5 antibody attenuated beta-catenin activity, inhibited cell growth, and induced apoptosis in LRP5Delta-positive MCF7 and T-47D breast cancer cells, but not in control cells. CONCLUSIONS/SIGNIFICANCE: Our results suggest that the LRP5Delta receptor is strongly implicated in mammary gland tumorigenesis and that its aberrant expression present an early event during disease progression. LRP5 antibody therapy may have a significant role in the treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.